MaMaLoc: Magnetic Marker Localisation for Breast Cancer

Summary

Over the past decades, Breast Conserving Surgery (BCS) has become the cornerstone of breast cancer treatment. Concurrently, the incidence of small and clinically occult breast lesions has risen sharply. For these lesions, surgical localization technologies are indispensable in guiding the surgeon to the correct tumor location to minimize the amount of healthy tissue resected and improve cosmetic outcome and, in turn, quality of life. Unfortunately, all currently available localization technologies suffer from significant disadvantages ranging from poor accuracy and patient unfriendliness (wire-guided localization) to poor clinical adoption due to legislative and regulatory challenges (radioactive seed localization). Over the past two years we have developed the MaMaLoc technology: a novel intra-operative localization technology based upon the physical principle of magnetism, rather than radioactivity. This answers the urgent clinical need for patient-friendly, logistically flexible and hassle-free tumor localization. During a Phase I Take-Off project we have gathered extensive preclinical feasibility data, with positive results across the board. In the current proposal we aim to take the MaMaLoc venture to the next level by setting up a large clinical trial that will form the basis of our commercialization, as well as a health technology assessment and incorporating the necessary RA, QA, IP and commercial knowledge within the venture.

Details

Project number

15251

Main applicant

Prof. dr. T.J.M. Ruers

Affiliated with

Nederlands Kanker Instituut, Antoni van Leeuwenhoek Ziekenhuis, Chirurgische Oncologie

Duration

13/03/2017 to 01/07/2018

Budget

EUR448,100